These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38357875)

  • 1. The Impact of Balloon Pre-dilatation Techniques on Drug-Coated Balloon Therapy for Femoropopliteal Artery Disease: Six-Month Results From the CIVILIAN Registry.
    Ye M; Ni Q; He C; Shi Z; Shi W; Zhu J; Li L; Wu Z
    J Endovasc Ther; 2024 Feb; ():15266028241231036. PubMed ID: 38357875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Chocolate percutaneous transluminal angioplasty balloon on vessel preparation in drug-coated balloon angioplasty for femoropopliteal lesion.
    Shirai S; Mori S; Yamaguchi K; Mizusawa M; Chishiki T; Makino K; Honda Y; Tsutsumi M; Hiraishi M; Kobayashi N; Yamawaki M; Ito Y
    CVIR Endovasc; 2022 Sep; 5(1):46. PubMed ID: 36048380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study).
    Shishehbor MH; Zeller T; Werner M; Brodmann M; Parise H; Holden A; Lichtenberg M; Parikh SA; Kashyap VS; Pietras C; Tirziu D; Ardakani S; Beschorner U; Krishnan P; Niazi KA; Wali AU; Lansky AJ
    Circulation; 2022 May; 145(22):1645-1654. PubMed ID: 35377157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Stented vs Nonstented Femoropopliteal Lesions Treated With Drug-Coated Balloon Angioplasty.
    Giannopoulos S; Strobel A; Rudofker E; Kovach C; Kokkosis AA; Armstrong EJ
    J Endovasc Ther; 2023 Apr; 30(2):194-203. PubMed ID: 35179065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stent Graft vs Drug-Coated Balloon in Endovascular Treatment of Complex Femoropopliteal Artery Lesions: A 2-Center Experience.
    Ye M; Ni Q; Zhu Y; Du Y; Wang Y; Guo X; Zhang L; Feng Z
    J Endovasc Ther; 2023 Sep; ():15266028231201097. PubMed ID: 37728023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis.
    Giannopoulos S; Ghanian S; Parikh SA; Secemsky EA; Schneider PA; Armstrong EJ
    J Endovasc Ther; 2020 Aug; 27(4):647-657. PubMed ID: 32508220
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcomes and Comparative Analysis of the Initial Results of Standard Balloon Angioplasty Versus Drug-Coated Balloons Alone Versus in Association With Laser-Excimer Atherectomy in the Treatment of Femoropopliteal Artery In-Stent Restenosis (INTACT).
    Ducasse E; Sapoval M; Brunet J; Commeau P; Goueffic Y; Sabatier J; Steinmetz E; Lermusiaux P; Rosset E; Caradu C
    J Endovasc Ther; 2024 Apr; ():15266028241248333. PubMed ID: 38659343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Intraluminal Drug-Coated Balloon Versus Drug-Eluting Stent in Patients With Chronic Total Occlusion of the Superficial Femoral Artery: A Retrospective Analysis.
    Hayakawa N; Kodera S; Takanashi K; Kanagami T; Ichihara S; Arakawa M; Hirano S; Inoguchi Y; Shakya S; Kanda J
    Cardiovasc Revasc Med; 2022 Oct; 43():87-96. PubMed ID: 35469761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Eluting Stent vs. Drug Coated Balloon for Native Femoropopliteal Artery Disease: A Two Centre Experience.
    Lee YJ; Kook H; Ko YG; Yu CW; Joo HJ; Ahn CM; Choi D
    Eur J Vasc Endovasc Surg; 2021 Feb; 61(2):287-295. PubMed ID: 33223281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease.
    Bausback Y; Wittig T; Schmidt A; Zeller T; Bosiers M; Peeters P; Brucks S; Lottes AE; Scheinert D; Steiner S
    J Am Coll Cardiol; 2019 Feb; 73(6):667-679. PubMed ID: 30765033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Rotational Atherectomy Followed by Drug-coated Balloon Angioplasty for the Treatment of Femoropopliteal Lesions-Comparison with Sole Drug-coated Balloon Revascularization: Two-year Outcomes.
    Rodoplu O; Oztas DM; Meric M; Beyaz MO; Ulukan MO; Yildiz CE; Unal O; Ugurlucan M
    Ann Vasc Surg; 2021 May; 73():222-233. PubMed ID: 33359329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Eluting Balloon Versus Drug-Eluting Stent for Complex Femoropopliteal Arterial Lesions: The DRASTICO Study.
    Liistro F; Angioli P; Porto I; Ducci K; Falsini G; Ventoruzzo G; Ricci L; Scatena A; Grotti S; Bolognese L
    J Am Coll Cardiol; 2019 Jul; 74(2):205-215. PubMed ID: 31296293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propensity score-matched analysis of six-month outcomes of paclitaxel-coated balloons combined with UltraScore balloons versus conventional scoring balloons for femoropopliteal lesions.
    Haraguchi T; Tsujimoto M; Otake R; Kashima Y; Sato K; Fujita T
    Diagn Interv Radiol; 2023 May; 29(3):535-541. PubMed ID: 37067068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
    Scheinert D; Duda S; Zeller T; Krankenberg H; Ricke J; Bosiers M; Tepe G; Naisbitt S; Rosenfield K
    JACC Cardiovasc Interv; 2014 Jan; 7(1):10-9. PubMed ID: 24456716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Predictors Influencing Restenosis Following High-Dose Drug-Coated Balloon Angioplasty and Fluoropolymer-Based Drug-Eluting Stenting in Femoropopliteal Artery Lesions.
    Kurata N; Iida O; Takahara M; Asai M; Okamoto S; Ishihara T; Nanto K; Tsujimura T; Hata Y; Toyoshima T; Higashino N; Nakao S; Mano T
    J Endovasc Ther; 2023 Nov; ():15266028231209234. PubMed ID: 37933462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laser Atherectomy Combined With Drug-Coated Balloon Angioplasty Is Associated With Improved 1-Year Outcomes for Treatment of Femoropopliteal In-Stent Restenosis.
    Kokkinidis DG; Hossain P; Jawaid O; Alvandi B; Foley TR; Singh GD; Waldo SW; Laird JR; Armstrong EJ
    J Endovasc Ther; 2018 Feb; 25(1):81-88. PubMed ID: 29219030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.
    Kokkinidis DG; Behan S; Jawaid O; Hossain P; Giannopoulos S; Singh GD; Laird JR; Valle JA; Waldo SW; Armstrong EJ
    Catheter Cardiovasc Interv; 2020 Feb; 95(3):439-446. PubMed ID: 31816169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat drug-coated balloon angioplasty for femoropopliteal lesions: 12-month results from a retrospective observational study.
    Haraguchi T; Tsujimoto M; Kashima Y; Sato K; Fujita T
    CVIR Endovasc; 2024 Feb; 7(1):24. PubMed ID: 38421471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-Year Safety and Effectiveness of Paclitaxel Drug-Coated Balloons Alone or With Provisional Bare Metal Stenting for Real-World Femoropopliteal Lesions: IN.PACT Global Study Subgroup Analysis.
    Ansel GM; Brodmann M; Rocha-Singh KJ; Menk JS; Zeller T;
    Circ Cardiovasc Interv; 2024 Feb; 17(2):e013084. PubMed ID: 38348677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.